RA Capital Management files initial beneficial ownership statement in Inhibikase Therapeutics

• RA Capital Management filed a Form 3 showing beneficial ownership of 25 million Inhibikase Therapeutics common shares.
• The filing lists RA Capital as a 10% owner, with the position reported as indirect ownership.
• The event date was July 10, 2026; the statement was signed and dated July 17, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inhibikase Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001231919-26-000769), on July 17, 2026, and is solely responsible for the information contained therein.